Active Ingredient(s): Insulin Degludec + Liraglutide
FDA Approved: * November 21, 2016
Pharm Company: * NOVO NORDISK INC
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Xultophy Overview

Insulin degludec/liraglutide, sold under the brand name Xultophy, is a fixed-dose combination medication for the treatment of adults with type 2 diabetes to improve glycemic control in combination with diet and exercise.[4][5] It contains insulin degludec and liraglutide.[4][5] It is administered by subcutaneous injection.[4][5] The most common side effects include hypoglycaemia (low blood glucose)...

Read more Xultophy Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Liraglutide/insulin_degludec

Recent Xultophy Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Insulin Degludec + Liraglutide
  • Injection: 100units + 3.6mg
  • Solution: 300 Units/3ml + 10.8mg/3ml (100 Units/ml + 3.6mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Drugs with one or more similar ingredients: (8 results)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 31 July 2021.

We are committed to your privacy.

Copyright © 2005-2021 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA